Decoy Therapeutics Inc. (DCOY)vsRevolution Medicines Inc (RVMD)
DCOY
Decoy Therapeutics Inc.
$5.54
+1.19%
HEALTHCARE · Cap: $2.89M
RVMD
Revolution Medicines Inc
$140.55
-2.96%
HEALTHCARE · Cap: $29.88B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. DCOY earns a higher WallStSmart Score of 26/100 (F).
DCOY
Avoid26
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 17.0x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : DCOY
The strongest argument for DCOY centers on Price/Book.
Bull Case : RVMD
The strongest argument for RVMD centers on Altman Z-Score.
Bear Case : DCOY
The primary concerns for DCOY are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.01 — expect wider price swings.
DCOY is growing revenue faster at 0.0% — sustainability is the question.
DCOY generates stronger free cash flow (-1M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DCOY scores higher overall (26/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Decoy Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. The company is headquartered in Cambridge, Massachusetts.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?